Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0FDBDQ
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
CN105051032B ADC-I-26
|
|||||
| Synonyms |
CN105051032B ADC-I-26
Click to Show/Hide
|
|||||
| Organization |
Celltrion, Inc.?
|
|||||
| Drug Status |
Investigative
|
|||||
| Indication |
In total 1 Indication(s)
Breast cancer [ICD11:2C60-2C65]
Investigative
|
|||||
| Drug-to-Antibody Ratio |
4.63
|
|||||
| Antibody Name |
Trastuzumab
|
Antibody Info | ||||
| Antigen Name |
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
|
Antigen Info | ||||
| Payload Name |
Undisclosed
|
|||||
| Linker Name |
CN105051032B_ADC-I-26 linker
|
|||||
General Information of The Activity Data Related to This ADC
Discovered Using Cell Line-derived Xenograft Model
Revealed Based on the Cell Line Data
| Standard Type | Value | Units | Cell Line | Disease Model |
|---|---|---|---|---|
| Half Maximal Effective Concentration (EC50) |
4.17
|
ng/mL
|
CVCL_0179
|
Invasive breast carcinoma
|
Full List of Activity Data of This Antibody-drug Conjugate
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≐ 45.00% (Day 28) | Positive HER2 expression (HER2+++/++) | ||
| Method Description |
Cells were subcutaneously inoculated at a dose of 1,000,000 cells to the right flank region of each female nude mouse (Day 0). On the day 7 of grouping, the antibody-drug conjugate was intravenously administered at doses of 0.5 mg/kg, iv.*1 to thetail of each mouse.
|
||||
| In Vivo Model | BT-474 CDX model | ||||
| In Vitro Model | Invasive breast carcinoma | BT-474 cells | CVCL_0179 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≐ 47.50% (Day 28) | Positive HER2 expression (HER2+++/++) | ||
| Method Description |
Cells were subcutaneously inoculated at a dose of 1,000,000 cells to the right flank region of each female nude mouse (Day 0). On the day 7 of grouping, the antibody-drug conjugate was intravenously administered at doses of 0.05 mg/kg, iv.*1 to thetail of each mouse.
|
||||
| In Vivo Model | BT-474 CDX model | ||||
| In Vitro Model | Invasive breast carcinoma | BT-474 cells | CVCL_0179 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≐ 87.50% (Day 28) | Positive HER2 expression (HER2+++/++) | ||
| Method Description |
Cells were subcutaneously inoculated at a dose of 1,000,000 cells to the right flank region of each female nude mouse (Day 0). On the day 7 of grouping, the antibody-drug conjugate was intravenously administered at doses of 5 mg/kg, iv.*1 to thetail of each mouse.
|
||||
| In Vivo Model | BT-474 CDX model | ||||
| In Vitro Model | Invasive breast carcinoma | BT-474 cells | CVCL_0179 | ||
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) | 4.17 ng/mL | Positive HER2 expression (HER2+++/++) | ||
| Method Description |
The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.
Click to Show/Hide
|
||||
| In Vitro Model | Invasive breast carcinoma | BT-474 cells | CVCL_0179 | ||
References
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.